The transferrin (TfR)-conjugated LNPs achieved 89% glioblastoma accumulation by exploiting TfR overexpression (10,000 receptors/cell) on blood–brain barrier endothelial cells, outperforming passive targeting by 41% [70]. Here, TFRC is linked to glioblastoma.